Poor
Not Aligned
Patient Risk:
Low
Summary
Only the indication list contents were provided from the label, but the AI response contains multiple non-label claims about generic availability/patent tracking/launch timing that are not supported by the supplied prescribing information and cannot be verified as label-consistent.
Category Scores
Accurate Statements
Unsupported Statements
Empagliflozin is marketed in the U.S. under brand names such as Jardiance.
The supplied prescribing information excerpt includes indications and does not provide information about brand naming/marketed brand names.
Whether generic empagliflozin products are available in 2026 depends on when specific patents and regulatory exclusivities covering each strength/formulation expire and when approved applicants launch.
The supplied prescribing information excerpt does not discuss generic availability, patent/exclusivity mechanics, strength/formulation differentiation, or launch timing.
DrugPatentWatch.com tracks patent and exclusivity status for drugs like empagliflozin.
The supplied prescribing information excerpt does not mention DrugPatentWatch.com or any third-party tracking services.
Generic timelines usually hinge on the expiration of relevant composition-of-matter or formulation patents.
The supplied prescribing information excerpt does not discuss patent types or generic timeline determinants.
Generic timelines usually hinge on the expiration of regulatory exclusivities that delay approval-to-market.
The supplied prescribing information excerpt does not discuss regulatory exclusivities or their impact on timelines.
Patent calendars can differ by country, dosage form, and whether a company is challenging or launching at risk.
The supplied prescribing information excerpt does not discuss country-by-country patent calendars or at-risk launch/challenge practices.
In some cases, patients may see authorized generics marketed under a different label but approved as the same active ingredient.
The supplied prescribing information excerpt does not discuss authorized generics or labeling practices.
In some cases, patients may see other SGLT2 inhibitors already available generically even if empagliflozin itself is still under brand protection.
The supplied prescribing information excerpt does not discuss other SGLT2 inhibitors’ generic status or brand protection timelines.
Launch timing can vary by country and local approvals.
The supplied prescribing information excerpt does not discuss launch timing variability by country or approvals.
Launch timing can vary by strength.
The supplied prescribing information excerpt does not discuss strength-dependent launch timing.
Launch timing can vary based on supply contracts and distribution ramp up after approval.
The supplied prescribing information excerpt does not discuss supply contracts or distribution timing.
DrugPatentWatch.com can be used to validate what should be available in 2026 by checking the latest patent position and any listed generic or ANDA candidates for empagliflozin.
The supplied prescribing information excerpt does not mention DrugPatentWatch.com, ANDA candidates, or using any source to validate availability.
Contradictions
Important Omissions
No drug-label statements related to FDA-approved indications, dosage/administration, contraindications, warnings/precautions, drug interactions, adverse reactions, monitoring, administration, or storage were provided in the AI response for auditing against the label beyond generic-brand/timeline claims.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
The provided AI response is primarily about generic availability/patents and does not make dosing, contraindication, warning, or safety claims that would directly conflict with labeled safety information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Major parts of the response are not supported or addressed by the supplied FDA prescribing information (indications excerpt only).
Suggested Improvement
Limit the audited statements to content actually present in the provided label excerpt, and if auditing other label elements (dosage, contraindications, warnings, etc.), provide the corresponding FDA label sections and the exact AI-generated statements to compare.